Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone
In Brief: FCRF Contract Hopefuls Make Oral Presentation; Jane Rowley To Deliver Karnofsky Lecture
Will Latest Report By Rosenberg Stir Up Critics? Some DCT Board Members Defend the Press
“Official Chronology” Of Gall/Montagnier Finding Agreed On; Royalties to Fund AIDS research
Spartanburg CCOP Makes the List
WETA Relents Will Air Documentary
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup - The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access









